Search results for " immunoglobulin g"

showing 3 items of 13 documents

A lethal Tick-Borne Encephalitis (TBE) due to TBE virus in Sicily (Italy): A case of IgG+/IgM-response?

2018

Tick-borne encephalitis (TBE) is an important viral infection of the central nervous system with high morbidity and mortality. With the increase of tourism TBE is becoming a problem also outside endemic regions. Italy is considered a country with low incidence of TBE and geographically restricted to the central and north eastern part of the country. In the south of Italy there is no evidence of disease presence, but neither is there much evidence of its absence. We report our experience about a lethal case of meningoencephalitis with a single-phase clinical course of the disease likely due to TBEV infection in a 13-year-old man. This is the first report of an autochthonous case of TBE in Si…

Tick-BorneTick-borne encephalitiMaleAdolescentAnimalMedicine (all)IncidenceEncephalitis Viruses Tick-BorneEncephalitis VirusesImmunoglobulin MFatal caseImmunoglobulin GFatal case; Ig-M negative; TBEV in Sicily; Tick-borne encephalitis; Adolescent; Animals; Encephalitis Viruses Tick-Borne; Encephalitis Tick-Borne; Humans; Immunoglobulin G; Immunoglobulin M; Incidence; Male; Sicily; Medicine (all)Tick-borne encephalitisEncephalitisAnimalsHumansIg-M negativeTBEV in SicilySicilyEncephalitis Tick-BorneHuman
researchProduct

Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma

2019

Background: CD8+ T cell responses are an essential component of the adaptive immune system. After resolution of infection a small population of memory cells is formed. In relation to circulatory patterns, different subsets of memory CD8+ T cells can be identified: the central memory (CM) and the effector memory T cells (EM) (Martin MD, et al., Front Immunol. 2018). In addition, it has been described a subset of resident memory T cells (TRM) permanently living in peripheral tissues, including the bone marrow (BM) (Di Rosa F., et al., Nat Rev Immunol. 2016). It is conceivable that these cells can contribute to the defence toward haematological tumours infiltrating the BM. Therefore, we perfor…

education.field_of_studymedicine.medical_treatmentT cellCD3ImmunologyPopulationCell BiologyHematologyBiologyBiochemistryMolecular biologySettore MED/15 - Malattie Del SangueCytokinemedicine.anatomical_structurebone marrow multiple myeloma t-lymphocytes memory cytokine interleukin-15 interleukin-7 cd45 antigens immunoglobulin a immunoglobulin g ki-67 antigenInterleukin 15medicinebiology.proteinCytotoxic T cellBone marroweducationCD8Blood
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct